Forte Biosciences (NASDAQ:FBRX) Sets New 1-Year High – What’s Next?

Shares of Forte Biosciences, Inc. (NASDAQ:FBRX) reached a new 52-week high on Thursday . The stock traded as high as $36.20 and last traded at $37.16, with a volume of 3859124 shares trading hands. The stock had previously closed at $20.58.

Key Headlines Impacting Forte Biosciences

Here are the key news stories impacting Forte Biosciences this week:

• Positive Sentiment: FB102 delivered statistically significant improvement in vitiligo in a placebo-controlled Phase 1b study, with early signs of benefit and favorable safety data. FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
• Positive Sentiment: Early-stage results are convincing investors that FB102 could be a broader autoimmune platform, not just a single-indication drug, which raises the longer-term commercial opportunity. Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet
• Positive Sentiment: Media reports highlighted a major jump in the share price after the trial update, reflecting heavy speculative demand around the data readout. Forte Biosciences shares surge after positive phase 1b vitiligo results
• Neutral Sentiment: The company’s cash position appears strong enough to fund development for multiple quarters, which supports execution but is not an immediate catalyst on its own. Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet

Analyst Ratings Changes

A number of research analysts have recently issued reports on FBRX shares. Wall Street Zen upgraded shares of Forte Biosciences from a “strong sell” rating to a “sell” rating in a research report on Monday, May 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Forte Biosciences in a research report on Wednesday. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Forte Biosciences has a consensus rating of “Moderate Buy” and an average price target of $67.00.

Forte Biosciences Trading Up 19.7%

The firm has a market cap of $610.05 million, a price-to-earnings ratio of -9.47 and a beta of 2.85. The stock has a 50-day moving average of $21.35 and a 200-day moving average of $26.25.

Forte Biosciences (NASDAQ:FBRX) last issued its earnings results on Monday, May 11th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.08). As a group, research analysts expect that Forte Biosciences, Inc. will post -4.27 earnings per share for the current fiscal year.

Institutional Trading of Forte Biosciences

A number of large investors have recently modified their holdings of the company. Orbimed Advisors LLC lifted its position in Forte Biosciences by 101.8% in the 2nd quarter. Orbimed Advisors LLC now owns 1,196,955 shares of the company’s stock valued at $15,477,000 after purchasing an additional 603,867 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new position in Forte Biosciences in the 2nd quarter worth about $4,310,000. Cable Car Capital LP grew its holdings in Forte Biosciences by 127.7% in the 2nd quarter. Cable Car Capital LP now owns 500,000 shares of the company’s stock worth $6,465,000 after buying an additional 280,396 shares in the last quarter. Jain Global LLC bought a new position in Forte Biosciences in the 4th quarter worth approximately $5,520,000. Finally, Federated Hermes Inc. increased its position in Forte Biosciences by 8.0% in the 4th quarter. Federated Hermes Inc. now owns 1,765,516 shares of the company’s stock valued at $48,146,000 after acquiring an additional 130,136 shares during the period. Institutional investors and hedge funds own 77.63% of the company’s stock.

About Forte Biosciences

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.